Study on plasmablastic lymphoma patients
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study looks back at medical records and tissue samples from people diagnosed with plasmablastic lymphoma (PBL) between 2000 and 2022. It aims to learn more about the disease and may help improve future care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have been diagnosed with plasmablastic lymphoma (PBL) between January 1st, 2000 and December 31st, 2022
- Your diagnosis must be confirmed by a tissue sample (biopsy) read by a local pathologist
- You must be 18 years or older
- Your complete medical records must be available for the study team to review
- A sample of your tumor tissue (histopathological material) must be available for the study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests how well a combination of daratumumab, bortezomib, and dexamethasone works in people with plasmablastic lymphoma that has returned or did not respond to prior treatment. It aims to shrink measurable tumors and improve outcomes, including for some people living with HIV.
This trial tests a new drug called elranatamab in patients with plasmablastic lymphoma (a rare blood cancer) who have already completed their first treatment. The drug may help prevent the cancer from coming back or growing, and the trial includes patients with and without HIV.
This study looks back at the medical records of people with lymphoma to learn more about the disease. It does not involve any new treatments or tests—just reviewing what happened in the past.
This study looks at people whose diffuse large B-cell lymphoma came back as a slower-growing lymphoma. Doctors want to understand how and why this happens, using medical records from diagnosis through follow-up.
This trial looks at people with lymphoma that involves mainly the heart (and possibly the lining around the heart) and was treated first with chemotherapy plus an anti-CD20 antibody. The goal is to understand outcomes from this specific treatment approach in patients diagnosed over a defined time period.
This study creates a long-term database of patients with plasma cell disorders (such as multiple myeloma) to improve future care. You would be helping doctors learn more about these conditions by sharing your records over time.
Hear when a new Plasmablastic Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.